NasdaqGS:CRNXPharmaceuticals
Crinetics Pharmaceuticals (CRNX) TTM Loss Of US$465 Million Tests Bullish Long Term Narratives
Crinetics Pharmaceuticals (CRNX) closed out FY 2025 with Q4 revenue of US$6.2 million and a basic EPS loss of US$1.29, alongside a full year trailing basic EPS loss of US$4.95 on revenue of US$7.7 million. Over recent quarters the company has seen quarterly revenue move from US$0.14 million in Q3 2025 and US$1.03 million in Q2 2025 to US$6.2 million in Q4 2025, while quarterly basic EPS losses ranged between US$1.04 and US$1.38 per share across FY 2025. This provides context for investors as...